SUBSCRIBE
SUBSCRIBE
News   Drug Development

Intercytex Limited Starts Skin Graft Substitute Trial

February 19, 2007 | 
1 min read

LONDON (SHARECAST) - Intercytex enjoyed gains today as the cell therapy outfit focused on skin and hair regeneration said it has started a Phase I study to evaluate the safety and tolerability of skin graft substitute ICX-SKN.

Clinical research Phase I Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Human Nose Like Worker Is Going To Work. Vector Collage Illustration Against The Background Of The City
Immunology and inflammation
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac